N-glycan biosignatures as a potential diagnostic biomarker for earlystage pancreatic cancer

作     者：Yan-Rong Wen Xia-Wen Lin Yu-Wen Zhou Lei Xu Jun-Li Zhang Cui-Ying Chen Jian He 

作者机构：Department of Nuclear MedicineNanjing Drum Tower HospitalAffiliated Hospital of Medical SchoolNanjing UniversityNanjing 210008Jiangsu ProvinceChina Department of Research and DevelopmentSysdiagno(Nanjing)Biotech Co.LtdNanjing 210008Jiangsu ProvinceChina 

出 版 物：《World Journal of Gastrointestinal Oncology》 (世界胃肠肿瘤学杂志（英文版）（电子版）)

年 卷 期：2024年第16卷第3期

页      面：659-669页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：fundings for Clinical Trials from the Affiliated Drum Tower Hospital Medical School of Nanjing University No.2021-LCYJ-MS-11 

主　　题：Glycomics N-glycans Biomarkers Pancreatic cancer Predictive modeling 

摘      要：BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)has a poor prognosis,with a 5-year survival rate of less than 10%,owing to its late-stage *** detection of pancreatic cancer(PC)can significantly increase survival *** To identify the serum biomarker signatures associated with early-stage PDAC by serum N-glycan *** An extensive patient cohort was used to determine a biomarker signature,in-cluding patients with PDAC that was well-defined at an early stage(stages I and II).The biomarker signature was derived from a case-control study using a case-cohort design consisting of 29 patients with stage I,22 with stage II,4 with stage III,16 with stage IV PDAC,and 88 *** used multiparametric analysis to identify early-stage PDAC N-glycan signatures and developed an N-glycan sig-nature-based diagnosis model called the“Glyco-model.RESULTS The biomarker signature was created to discriminate samples derived from patients with PC from those of controls,with a receiver operating characteristic area under the curve of *** addition,the biomarker signature combined with cancer antigen 19-9 could discriminate patients with PDAC from controls,with a receiver operating characteristic area under the curve of ***-model demonstrated favorable diagnostic performance in all stages of *** diagnostic sensitivity for stage I PDAC was 89.66%.Core Tip:This study employed a patient cohort to investigate the N-glycan signature of early-stage pancreatic cancer(PC).Serum N-glycans analysis was conducted to identify the serum biomarker signature associated with early-stage pancreatic ductal adenocarcinoma(PDAC),resulting in the identification of nine early-stage PDAC N-glycan ***,utilizing these biosignatures,a diagnostic model named the“Glyco-modelwas developed,demonstrating promising diagnostic performance across all stages of *** study revealed that the diagnostic sensitivity for stage I PDAC was determined to be 89.66%.Co